Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | VDR | P11473 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855079 | 0.94 | CA1 (0.52) | CA1CA2VDRUSP2ST6GAL1 | |
| SCHEMBL22855365 | 0.90 | CA1 (0.65) | CA1CA2VDRUSP2ST6GAL1 | |
| SCHEMBL22855347 | 0.88 | VDR (0.65) | CA1CA2VDRUSP2ST6GAL1 | |
| SCHEMBL22855359 | 0.88 | CA1 (0.56) | CA1CA2VDRST6GAL1CYP2C9 | |
| SCHEMBL22855501 | 0.87 | VDR (0.72) | VDRUSP2ST6GAL1GPBAR1 | |
| SCHEMBL22855053 | 0.87 | VDR (0.72) | VDRUSP2ST6GAL1GPBAR1 | |
| SCHEMBL22855103 | 0.87 | VDR (0.72) | VDRUSP2ST6GAL1GPBAR1 | |
| SCHEMBL22855076 | 0.87 | CA1 (0.53) | CA1CA2VDRST6GAL1CYP2C9 | |
| SCHEMBL22855078 | 0.87 | CA1 (0.61) | CA1CA2VDRUSP2ST6GAL1 | |
| SCHEMBL22855058 | 0.86 | VDR (0.73) | VDRUSP2ST6GAL1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020260558-A1 | 3-MODIFIED ISO-/ISOALLO-LITHOCHOLIC ACID DERIVATIVES OR THEIR HOMO-ANALOGS FOR PREVENTING AND TREATING CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2020-12-30 | — | — | WO | disclosed |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | CA1 1490/4885CA2 351/4885VDR 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.